Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 88

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Hepato-lenticular degeneration

Not recruiting

Study of Trientine Dihydrochloride (Cufence) to Evaluate Its Effects and Safety in Patients with Wilson's Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Trientine Dihydrochloride
  • Sponsor:Univar Solutions B.V.

Multiple sclerosis

Not recruiting

Study on Amantadine and Transcranial Magnetic Stimulation for Reducing Fatigue in Multiple Sclerosis Patients

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Amantadine Hydrochloride
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos

Progressive supranuclear palsy

Not recruiting

Study of FNP-223 tablets to slow disease progression in patients with Progressive Supranuclear Palsy (PSP)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(S)-N-(5-(4-(1-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)Piperazin-1-Yl)-1,3,4-Thiadiazol-2-Yl)Acetamide, Hydrochloride Salt
  • Sponsor:Ferrer Internacional S.A.

Aicardi-Goutieres syndrome

Not recruiting

Study on the Safety of Censavudine (TPN-101) for Patients with Aicardi-Goutières Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Censavudine
  • Sponsor:Transposon Therapeutics Inc.

Fabry's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Pegunigalsidase Alfa for Adults with Fabry Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Pegunigalsidase Alfa
  • Sponsor:Chiesi Farmaceutici S.p.A.

Human herpesvirus 6 encephalitis

Not recruiting

Study on Dexamethasone for Patients with Herpes Simplex Virus Encephalitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire Grenoble Alpes

Spinal muscular atrophy+1

Not recruiting

Study of Clenbuterol vs Placebo in Adult Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clenbuterol Hydrochloride
  • Sponsor:Azienda Ospedaliera di Padova

Metachromatic leukodystrophy

Not recruiting

Study of Intrathecal Cebsulfase Alfa for Children with Late Infantile Metachromatic Leukodystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Severe myoclonic epilepsy of infancy+1

Not recruiting

Long-Term Safety Study of Fenfluramine Hydrochloride for Seizures in Patients with Dravet or Lennox-Gastaut Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:Zogenix International Limited

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Cls12311
  • Sponsor:Cellerys AG

Arterial disorder+1

Not recruiting

Study on Cerebrolysin and Sodium Chloride for Patients with CADASIL

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ever Neuro Pharma GmbH

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.